GW 9578 

GW9578 is a subtype-selective PPARα agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity^[1][2].

GW9578 exhibits activities on Murine PPAR-α, PPAR-γ, and PPAR-δ with EC₅₀s of 0.005, 1.5, 2.6 μm, respectively. GW9578 exhibits activities on Human PPAR-α, PPAR-γ, and PPAR-δ with EC₅₀s of 0.05, 1, and 1.4 μm, respectively^[2].
Treatment of the CD8⁺ T-cell line, TK.1 cells with GW9578 (10 nM-1 μM; for 24 hours) is able to induce a dose-dependent increase in the amount of relative luciferase activity^[3].
Treatment of murine T-cell thymoma EL-4 T cells with GW9578 (10 nM-10 μM; for 2 hours) leads to a significant decrease in IL-2 production compared with control cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

492.62

C₂₆H₃₄F₂N₂O₃S

247923-29-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. P J Brown, et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem. 1999 Sep 23;42(19):3785-8.  [Content Brief]

  [2]. Alexandre Trifilieff, et al. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003 May;139(1):163-71.  [Content Brief]

  [3]. Dallas C Jones, et al. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem. 2002  [Content Brief]